Literature DB >> 24273644

Discovery of a Pair of Diastereomers as Potent HDACs Inhibitors: Determination of Absolute Configuration, Biological Activity Comparison and Computational Study.

Yingjie Zhang1, Elizabeth S Inks, Mengyuan Zhu, C James Chou, Hao Fang, Minyong Li, Yuemao Shen, Fan Yi, Wenfang Xu.   

Abstract

Histone deacetylase inhibitors (HDACi) are still the focus of epigenetic modulator development due to their effective intervention in many pathological processes. In our previous research, a potent HDACi was designed, synthesized and validated as a promising antitumor candidate named ZYJ-34c. Enlarged scale synthesis of ZYJ-34c for further detailed research was hindered by the occurrence of a by-product, which was identified as an isomer of ZYJ-34c by HRMS and 1H NMR. Subsequent synthesis route modification and optimization revealed that these two isomers were a pair of epimers and their absolute configurations could be directly determined by our optimized synthesis routes, through which each optically pure epimer could be stereoselectively synthesized, respectively. Based on these results, we concluded that our previously reported absolute configuration of ZYJ-34c was incorrect. It is worth noting that the epimer of ZYJ-34c exhibited more potent HDACs inhibition and both in vitro and in vivo antitumor activities, and moreover, their different HDACs inhibitory activities could be rationalized by computational simulations of their binding modes in HDAC2.

Entities:  

Year:  2013        PMID: 24273644      PMCID: PMC3836556          DOI: 10.1039/C3RA43249A

Source DB:  PubMed          Journal:  RSC Adv        ISSN: 2046-2069            Impact factor:   3.361


  9 in total

Review 1.  Developing histone deacetylase inhibitors as anti-cancer therapeutics.

Authors:  B Venugopal; T R J Evans
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 2.  Epigenetic regulation in psychiatric disorders.

Authors:  Nadia Tsankova; William Renthal; Arvind Kumar; Eric J Nestler
Journal:  Nat Rev Neurosci       Date:  2007-05       Impact factor: 34.870

3.  An operational definition of epigenetics.

Authors:  Shelley L Berger; Tony Kouzarides; Ramin Shiekhattar; Ali Shilatifard
Journal:  Genes Dev       Date:  2009-04-01       Impact factor: 11.361

4.  Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors.

Authors:  Yingjie Zhang; Jinhong Feng; Chunxi Liu; Lei Zhang; Jie Jiao; Hao Fang; Li Su; Xiaopan Zhang; Jian Zhang; Minyong Li; Binghe Wang; Wenfang Xu
Journal:  Bioorg Med Chem       Date:  2010-02-06       Impact factor: 3.641

Review 5.  Histone deacetylase: a regulator of transcription.

Authors:  A P Wolffe
Journal:  Science       Date:  1996-04-19       Impact factor: 47.728

6.  Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities.

Authors:  Yingjie Zhang; Hao Fang; Jinhong Feng; Yuping Jia; Xuejian Wang; Wenfang Xu
Journal:  J Med Chem       Date:  2011-07-11       Impact factor: 7.446

Review 7.  The epigenomics of cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Cell       Date:  2007-02-23       Impact factor: 41.582

8.  Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.

Authors:  Yingjie Zhang; Jinhong Feng; Yuping Jia; Xuejian Wang; Lei Zhang; Chunxi Liu; Hao Fang; Wenfang Xu
Journal:  J Med Chem       Date:  2011-04-05       Impact factor: 7.446

Review 9.  Epigenetic opportunities and challenges in cancer.

Authors:  Jonathan D Best; Nessa Carey
Journal:  Drug Discov Today       Date:  2009-11-06       Impact factor: 7.851

  9 in total
  1 in total

1.  Many-molecule encapsulation by an icosahedral shell.

Authors:  Jason D Perlmutter; Farzaneh Mohajerani; Michael F Hagan
Journal:  Elife       Date:  2016-05-11       Impact factor: 8.140

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.